Citations

Clear

4510 citation(s) found for "Scott, C".

Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
Smith, Ellen M. Lavoie, Lee, Minji K. , Scott, Mary R , Liu, Heshan , Hillman, S. L., Rieken, Tracy L., Wills, Rachel, Diaz-Cobo, Julian, Chow, Selina, Finnes, Heidi D. , Ruddy, Kathryn, O'Reilly, Eileen, Baghdadi, Tareq Al, Florez, Narjust, Kharofa, Jordan , Govindarajan, Rang, Tejani, Mohamedtaki Abdulaziz, Chung, Ki, Zahrieh, David, Loprinzi, Charles, Lustberg, M., Lavoie Smith, Ellen M , Lee, Minji K , Scott, Mary R , Hillman, Shauna, Rieken, Tracy , Ruddy, Kathryn J , Meyerhardt, Jeffrey A , O'Reilly, Eileen M , Baghdadi, Tareq Al , Duma, Narjust , Govindarajan, Rang , Zahrieh, David , Loprinzi, Charles , Lustberg, Maryam , Hillman, Shauna L., Wills, Rachel, Ruddy, Kathryn J. , Meyerhardt, Jeffrey A. , Florez, Narjust , Zahrieh, David , Loprinzi, Charles L. , Lustberg, Maryam B.

Mayo Clinic

JCO Oncology Advances | March 25, 2026 | Volume: 3 | Issue: 1 | Pages: No page available

10.1200/oa-25-00107 | PMID 42052361 Get It

PURPOSE The primary objective of this randomized, double-blind, placebo-controlled, multicenter phase II study (Alliance A221805) was to screen two doses of duloxetine for preventing sensory oxaliplatin-induced peripheral neuropathy (OIPN). METHODS Participants were randomly assigned 1:1:1 to receive once daily 30 mg duloxetine, 60 mg duloxetine, or placebo. Eligible participants had stage II to III colorectal cancer and no baseline neuropathy, had Eastern Cooperative Oncology Group performance status 0-2, were age 25 years and older, and received oxaliplatin via one of the following doses and schedules: 85 mg/m 2 every 2 weeks (6 or 12 doses) or 130 mg/m 2 every 3 weeks (4 doses). Duloxetine/placebo was taken once daily beginning day 1 of cycle 1 and continued for 17 weeks. The primary end point, a composite response reflecting sensory OIPN symptom severity and onset, was measured in weeks 19-21 using a validated participant-reported outcome survey assessing extremity numbness, tingling, and pain. Response was defined as a participant-reported highest score of ≤2 (ie, 1 = not at all; 2 = a little) on survey items. To be evaluable for the response end point, eligible participants must have initiated oxaliplatin and submitted ≥1 postbaseline OIPN survey. RESULTS Of the 199 participants (n = 66, 30 mg duloxetine; n = 66, 60 mg duloxetine; n = 67, placebo), 46, 47, and 50 (N = 143, 71.8%), respectively, were evaluable for primary end point analysis based on modified intention-to-treat criteria. Participant mean age was 55.1 years (standard deviation = 10.4). Most were White (n = 113, 80.7%) and male (n = 82, 58.6%). The proportion of responders among those receiving placebo (68.0%) was similar to those receiving duloxetine 30 mg (65.2%) or 60 mg (66.0%). Duloxetine adherence rates, measured via pill counts—30 mg (54%), 60 mg (57%), and placebo (59%) groups—were low (<75%). CONCLUSION Duloxetine is not more promising than placebo for preventing sensory OIPN.
Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease
O'Sullivan, D, Samimi, Sahar , Anjewierdan, Scott , Wi, Chung‐Il, Lopez, Keila N. , Egbe, Alexander, Watson, Dave , Jain, C. Charlie, Juhn, Young J. , Miranda, William R. , Connolly, Heidi M., Madhavan, Malini, Burchill, Luke J., Wi, Chung‐Il , O’Sullivan, Donnchadh , O'Sullivan, Donnchadh , Wi, Chung-Ii , Egbe, Alexander C , Charles Jain, C , Connolly, Heidi M , Madhavan, Malini , Burchill, Luke J , Lopez, Keila N , Anjewierden, Scott , Jain, C. Charles , Connolly, Heidi M. , Madhavan, Malini , Burchill, Luke J.

Mayo Clinic

Journal of the American Heart Association | March 25, 2026 | Volume: 15 | Issue: 7 | Pages: No page available

10.1161/jaha.125.045411 | PMID 41878868 Get It

Background Mortality in adults with congenital heart disease (CHD) is strongly driven by disease complexity. Social determinants of health (SDOH) influence adult CHD (ACHD) health outcomes but their impact on mortality is unclear. This study examined the influence of clinical factors and SDOH on all‐cause mortality in patients with ACHD. Methods Single‐center retrospective cohort study of patients with ACHD in the Mayo ACHD Registry who had a verifiable residential address between January 1, 2004 and December 31, 2023. Clinical and SDOH indicators were extracted, including insurance type, language, rural–urban commuting area code, and a housing‐based socioeconomic index, an individual‐level measure of socioeconomic status derived from 4 objective housing characteristics and categorized into quartiles (Q1–Q4). Cox proportional‐hazards models were fitted to evaluate associations with mortality, incorporating CHD severity, arrhythmias, SDOH indicators, and other comorbidities. County of residence was included as a random effect, and model discrimination was assessed using the concordance statistic. Results Among 6134 patients with ACHD, the mean age was 38±16 years; 51% were male; 78.7% were White and 44.9% had rural residence. Independent predictors of mortality included cyanotic CHD (adjusted hazard ratio [aHR], 5.70 [95% CI, 2.90–11.23]), Fontan palliation (aHR, 4.98 [95% CI, 2.56–9.70]), ventricular tachycardia (aHR, 1.71 [95% CI, 1.16–2.52]), older age at first visit (aHR, 1.05 per year [95% CI, 1.04–1.05]), male sex (aHR, 1.19 [95% CI, 1.03–1.39]), public insurance (aHR, 1.60 [95% CI, 1.35–1.90]), rural residence (aHR, 1.25 [95%, CI 1.06–1.47]), and non‐English language (aHR 1.75 [95% CI 1.38–2.23]). The housing‐based socioeconomic index quartile was not associated with mortality. The final model achieved a concordance statistic of 0.77. Conclusions Mortality in patients with ACHD is strongly influenced by both clinical factors and SDOH, independent of socioeconomic status. Addressing barriers to care such as language, insurance, and geography is essential for improving ACHD survival particularly in those at increased mortality risk.
The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus
Goldberg, Joseph F. , McIntyre, Roger S. , Mago, Rajnish, Jha, Manish K. , Berk, Michael , Kasper, Siegfried , Freeman, Marlene P. , GITLIN, MICHAEL J., Ostacher, Michael J. , Citrome, Leslie, Iosifescu, Dan V., Thase, Michael E., Young, Allan H. , Tohen, Mauricio, Nierenberg, Andrew A., Macaluso, Matt, Shelton, Richard C., Correll, Christoph U., Rosenblat, Joshua D., Gorwood, Philip, Khan, Arifulla, Kupka, Ralph, Cohen, Lawrence J., Mitchell, Philip B., Frye, Mark A., Sanacora, Gerard, Kane, John M., D, Goodman, Zohar, Joseph, Davis, Lori, Gupta, Swapnil , Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H., Cohen, Lawrence J. , McIntyre, Roger S , Malhi, Gin S , Jha, Manish K , Berk, Michael , Kasper, Siegfried , Sajatovic, Martha , Ostacher, Michael J , Perlis, Roy H , Furukawa, Toshi A , Vieta, E , Young, Allan H , Aaronson, Scott T , Rubio, Jose M , Swartz, Holly A. , Malhi, Gin S. , Gitlin, Michael , Citrome, Leslie , Vieta, Eduard , Thase, Michael E. , Tohen, Mauricio , Nierenberg, Andrew A. , Shelton, Richard C. , Correll, Christoph Ulrich , Rosenblat, Joshua D. , Gorwood, Philip , Kupka, Ralph , Mitchell, Philip B , Frye, Mark A. , Sanacora, Gerard , Kane, John M., Zohar, Joseph , Davis, Lori L. , Gupta, Swapnil, Zarate, Carlos A. , Clayton, Anita H.

Mayo Clinic

The British Journal of Psychiatry | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1192/bjp.2026.10580 | PMID 41877318 Get It

Summary The American Society of Clinical Psychopharmacology convened a 45-member international expert task force to identify circumstances supporting the deprescribing of core psychotropic medications for major depressive disorder (MDD) and bipolar disorders. Three Delphi survey rounds plus a selective literature review identified points of consensus (predefined as ≥75% agreement) about when antidepressant, antipsychotic, mood stabiliser and sedative-hypnotic deprescribing is warranted. Twenty out of 32 statements (63%) achieved consensus across seven thematic areas. In MDD, panellists favoured discontinuing antidepressants when mechanisms of action are duplicative, adequate trials produce ≤25% improvement or loss of prior efficacy cannot be regained through dose increases or augmentations. Indefinite antidepressant maintenance in MDD was favoured after three or more lifetime episodes. In bipolar disorder, antidepressant deprescribing was favoured in the setting of rapid cycling, mixed features or emerging mania/hypomania symptoms; and discouraged if prior antidepressant cessation led to relapse. In nonpsychotic mood disorders, panellists favoured deprescribing antipsychotics that caused significant weight gain or tardive dyskinesia over adding pharmacological antidotes. Deprescribing to achieve an eventual medication-free status was considered inappropriate, in bipolar type 1, but not necessarily bipolar type 2 disorder. Although individualised circumstances necessarily inform psychopharmacology management, clinical presentations that misalign with existing pharmacotherapies may signal the desirability of cautious deprescribing.
The blanking interval after atrial fibrillation ablation: time for reassessment with pulsed field energy
Rodriguez, Juan F. , Vemulapalli, Hema Srikanth , Kim, James Y. , Scott, Luis R. , Valverde, Arturo M. , Deshmukh, Abhishek , McLeod, Christopher J. , Srivathsan, Komandoor , Rodriguez-Riascos, Juan F , Vemulapalli, Hema S , Sardana, Mayank , Deshmukh, Abhishek J , Kapa, Suraj , McLeod, Christopher J , Srivathsan, Komandoor , Valverde, Arturo M , Kapa, Suraj , Kim, James

Mayo Clinic

Europace | March 25, 2026 | Volume: 28 | Issue: 3 | Pages: No page available

10.1093/europace/euag040 | PMID 41877360 Get It

Abstract Aims The clinical significance of early recurrences during the blanking period following pulmonary vein isolation (PVI) remains uncertain, particularly after pulsed field ablation (PFA). This study aimed to evaluate the prognostic impact of early recurrences at 30-, 60-, and 90-day thresholds on outcomes following PFA for atrial fibrillation (AF). Methods and results Consecutive patients who underwent PFA for AF across multiple centres within the Mayo Clinic health system were included. The primary endpoint was AF-free survival. Kaplan–Meier and multivariate Cox regression analyses were performed to compare outcomes between patients with and without early recurrences using 30-, 60-, and 90-day thresholds. A total of 1162 patients were included. The estimated AF-free survival at 1 year was 70%. Early recurrences within 30-, 60-, and 90-days post-ablation were significantly associated with late recurrences beyond 90 days (hazard ratio [HR] 5.9, 95% confidence interval [CI] 4.4–7.9, P &lt; 0.01; HR 6.6, 95% CI: 5.0–8.6, P &lt; 0.01; and HR 9.1, 95% CI: 7.0–11.7, P &lt; 0.01, respectively). These findings remained significant among patients undergoing continuous rhythm monitoring. Early recurrences within 30 days in this subgroup were significantly associated with a 1-year AF burden &gt;1% or the need for repeat AF ablation (odds ratio 25.0, 95% CI: 6.6–126.8, P &lt; 0.01). Conclusion Early recurrences following PFA are strongly predictive of long-term arrhythmia recurrence and are unlikely to represent transient inflammatory phenomena. Accordingly, the applicability of the conventional blanking interval after PFA should be reconsidered.
Performance of clinical breast cancer risk prediction models vs a mammography-based artificial intelligence risk model
Kaul, M., Scott, C., Wadzinske, Alena , Banerjee, Imon, Hursh, Dan, Norman, Aaron, Wu, Fang-Fang, Medero, Ramon Correa, Couch, Fergus, Pruthi, Sandhya , Olson, JA, Kerlikowske, Karla, Vachon, Celine M, Scott, Christopher G. , Couch, Fergus J. , Norman, Aaron D. , Banerjee, Imon , Correa, Ramón , Couch, Fergus J. , Kaul, Medha , Scott, Christopher , Banerjee, Imon , Norman, Aaron D , Correa-Medero, Ramon Luis , Kontos, Despina , McCarthy, Anne Marie , Winham, Stacey J , Kerlikowske, Karla M , Vachon, Celine M. , Pruthi, Sandhya , Hursh, Dan, Winham, Stacey J. , Kerlikowske, Karla

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 24, 2026 | Volume: 118 | Issue: 8 | Pages: 1485-1495

10.1093/jnci/djag083 | PMID 41885411 Get It

Abstract Background Artificial intelligence (AI)–based, mammography breast cancer risk prediction models show improved discriminatory accuracy relative to clinical risk models. However, data on their calibration are limited. This study compared model performance of 3 clinical breast cancer risk models: Gail, Tyrer–Cuzick v8, and Breast Cancer Surveillance Consortium v3 with the MIRAI AI-risk model. Methods Digital mammograms were ascertained from a screening mammography cohort of 12 308 women within the Mayo Clinic Biobank with 250 incident breast cancers (176 invasive) within 5 years. We predicted 5-year breast cancer risk, estimated discriminatory accuracy (C-index), and calibration (observed-to-expected ratio) of both overall and invasive breast cancer and compared estimates using bootstrapping approaches. Results MIRAI demonstrated similar or improved discriminatory accuracy of overall breast cancer (C-index = 0.71, 95% confidence interval [CI] = 0.68 to 0.74) and invasive breast cancer (C-index = 0.71, 95% CI = 0.67 to 0.75) compared with clinical models (overall breast cancer: C-index = 0.59-0.68; invasive breast cancer: C-index = 0.60-0.68). MIRAI’s calibration for risk of overall breast cancer (observed-to-expected ratio = 0.96, 95% CI = 0.85 to 1.08) was improved compared with Gail (observed-to-expected ratio = 1.22, 95% CI = 1.07 to 1.38) and Breast Cancer Surveillance Consortium (observed-to-expected ratio = 1.38, 95% CI = 1.22 to 1.56) but similar to TC with volumetric percent density and polygenic risk score (observed-to-expected ratio = 0.99, 95% CI = 0.87 to 1.13). However, for low-risk women (approximately 50%), MIRAI overestimated risk of overall breast cancer. MIRAI also overestimated risk of invasive breast cancer across the risk spectrum (observed-to-expected ratio = 0.68, 95% CI = 0.58 to 0.78), whereas clinical models had good calibration (observed-to-expected ratio = 0.86–0.99). Conclusion MIRAI demonstrated stronger discriminatory accuracy than clinical models for 5-year overall and invasive breast cancer risk prediction but overestimated risk for both breast cancer endpoints. AI-based risk models should consider discriminatory accuracy and calibration for invasive cancer before implementation.
1533: THROMBECTOMY WITH ALTEPLASE OR TENECTEPLASE: COMPARATIVE ANALYSIS FROM TRINETX REALWORLD DATA
Camp, Samantha , Rajaram, Kavya, Walker, Jennifer, Hintze, Trager, Polotti, Alyssa, Engstrom, Kellyn , Tran, Quincy, Najafali, Daniel , Pourmand, Ali , Tran, Quincy

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001188128.19145.21 Get It

TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
Stockard, Alyssa , Leibovit-Reiben, Zachary , Hu, Bowen , Jiang, Rundong , Roberts, Bryce T. , Penner, Scott , Li, Xing , Ramirez, Zeni , Stewart, Keegan , Fox, Jennifer , Bogle, Rachael , Zhang, Nan, Shao, Samantha C. , DiCaudo, David J. , Zunich, Samantha , Tsoi, L., Pittelkow, Mark R., Sluzevich, Jason C. , Gudjonsson, Johann E., Leibovit‐Reiben, Zachary , Zhang, Nan , Borges da Silva, Henrique , DiCaudo, David J , Zunich, Samantha , Pincelli, T , Tsoi, Lam C , Pittelkow, Mark R , Sluzevich, Jason C , Gudjonsson, Johann E , Mangold, A R , Penner, S.E., Ramirez, Z., Wasikowski, Rachael, Silva, Henrique Borges da , Pincelli, Thaís , Tsoi, Lam C. , Pittelkow, Mark R. , Mangold, Aaron R.

Mayo Clinic

No container title available | March 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.13.26348272 | PMID 41891048 Get It

Abstract Lichen Planopilaris (LPP) is a lymphocyte-mediated scarring alopecia characterized by progressive follicular destruction and fibrosis. In this clinical trial, patients with biopsy proven LPP were treated with deucravacitinib (an oral inhibitor of tyrosine kinase 2 (TYK2)) 6 mg BID for 24 weeks (NCT-06091956). Bulk and single-cell RNA sequencing was performed on paired pre- and post-treatment scalp biopsies from baseline and week 4. Patients (N=10) demonstrated improvements in PGA (88.9%, p=0.008), LPPAI (−2.3 points, SD 1.1, p=0.002) and Skindex-16 (−21.0 points, SD 22.1, p=0.014) scores at week 24. Bulk transcriptomic analysis of untreated LPP revealed upregulation of type I Interferon (IFN)-stimulated genes and pathways related to inflammation, immune activation, keratinization, and extracellular matrix remodelling, with downregulation of immune and inflammatory pathways following treatment. Single-cell RNA-seq of LPP was characterized by enrichment of CD8+GZMK+ T cells which showed downregulation of T-cell receptor signaling as well as antiviral pathways with treatment. Basal keratinocytes exhibited reduced cytokine and interferon signaling and decreased communication with NK cells following treatment. CCL19+ fibroblasts were prominent in untreated disease was attenuated after treatment, with downregulation of type I IFN signaling. Selective TYK2 inhibition with deucravacitinib effectively suppresses these inflammatory circuits in LPP and represents a promising therapeutic strategy.
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis
Vitis, Luigi Antonio De , Larson, Melissa C., Atkinson, Hunter J., Block, Matthew S. , CLIBY, W, Couch, Fergus J., Dowdy, Sean C., Glaser, Gretchen E., Goergen, Krista M., Goode, E., Gostout, Bobbie S., Hartmann, Lynn C., Heinzen, Ethan P. , Huang, Yajue, Jatoi, Aminah , Jones, Monica B., Karow, Katie J., Keeney, Gary L., Kumar, Amanika, Langstraat, Carrie L., Lee, Sun-Hee , Mariani, A., Ostby, Stuart A. , Peethambaram, Prema P. , Podratz, Karl C. , Shahi, Maryam , Sherman, M., Sommerfield, Marla Kay, Wall, Vonda M., Weroha, S. John, Hendrickson, Andrea E. Wahner , Maurer, Matthew J., Bakkum-Gamez, Jamie, Oberg, Ann L. , Cliby, William A. , Couch, Fergus J. , Larson, Melissa C. , Glaser, Gretchen , Couch, Fergus J. , De Vitis, Luigi A, Jones, Monica, Glaser, Gretchen , Larson, Melissa C , Cliby, William A , Atkinson, Hunter J., Dowdy, Sean C. , Hartmann, Lynn C. , Kumar, Amanika , Langstraat, Carrie , Sherman, Mark E. , Sommerfield, Marla-Kay, Swisher, Elizabeth M. , Wall, Vonda M., Maurer, Matthew J. , Kaufmann, Scott H. , Bakkum‐Gamez, Jamie N.

Mayo Clinic

JCO Oncology Advances | March 20, 2026 | Volume: 3 | Issue: 1 | Pages: No page available

10.1200/oa-25-00142 | PMID 41918500 Get It

PURPOSE To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved under changing treatment approaches. MATERIALS AND METHODS This is a retrospective cohort study including patients with histologically confirmed HGSOC treated at a single referral cancer center from 1991 to 2022. Mortality risk, expressed as standardized mortality ratios (SMRs, ratio of observed deaths in the study population to expected deaths in an age-matched US population), was assessed at diagnosis and yearly on patients without events (disease persistence, recurrence, or death from any cause). RESULTS A total of 2,074 consecutive patients were included. The median follow-up was 12.5 years (IQR, 11.7-13.8). Most patients were stage III (1,396, 69.2%), 1,299 (62.8%) underwent primary cytoreductive surgery, and 1,688 (87.4%) received platinum-taxane as first-line therapy. At diagnosis, the mortality rate was 7.40 times higher than that in the general population (95% CI, 7.04 to 7.77). By 7 event-free years, the 95% CI for the SMR included 1 for the first time, and at 10 years, the SMR was 1.05 (95% CI, 0.72 to 1.49), indicating no statistically significant excess mortality compared with the general population. In those event-free at 10 years, the 5-year cumulative incidence of ovarian cancer–related deaths (8.2% [95% CI, 4.2 to 16.0]) was comparable with that of non–ovarian cancer–related deaths (6.3% [95% CI, 2.9 to 13.8]). CONCLUSION In this cohort, mortality risk steadily declined for patients who remained event-free, approaching that of the general population by 7 years after diagnosis. These results emphasize the importance of individualized, long-term follow-up to address both recurrence risk and survivorship needs.
Estrogen receptor-positive cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma
Tasdemir, Nilgun , Scott, Julie A., Biery, Kyle, Li, Zheqi , Bossart, Emily A., Wang, Sarah , Nasrazadani, Azadeh , Qin, Ye Jun, Cao, Ye , Castro, Carlos A. , Davidson, Nancy E. , Oesterreich, Steffi, Li, Zheqi , Tseng, George , Hooda, Jagmohan , Lee, Adrian V , Savariau, Laura , Latoche, Joseph D. , Sreekumar, Sreeja , Brown, Daniel D. , Watters, Rebecca Jean , Chen, Fangyuan , Sikora, Matthew J. , Anderson, Carolyn J. , Atkinson, Jennifer M. , Lucas, Peter C. , Lee, Adrian V. , Oesterreich, Steffi

Mayo Clinic

No container title available | March 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.17.712396 | PMID 41890029 Get It

Invasive lobular breast carcinoma (ILC), the most common special histological subtype of breast cancer, is characterized by nearly universal expression of estrogen receptor alpha (ER) and unique sites of metastases, neither of which is fully recapitulated by genetically engineered mouse models. Using reporter-labeled ILC mouse xenografts, herein we used mammary fat pad, tail vein and intracardiac orthotopic growth to analyze spontaneous and experimental metastasis and gene expression. We observed ER-positive primary tumors with single-file histology and collagen deposition, and spontaneous metastasis from the mammary fat pad to bones, ovaries, and brain including the leptomeninges, thereby closely mirroring the growth and metastatic spread of human ILC. Brain metastases showed strong ER staining, confirmed by sequencing analyses which identified estrogen signaling as top activated pathway, and the lesions exhibited robust response to endocrine therapy. In summary, we report endocrine responsive mammary fat pad, tail vein and intracardiac xenografts that faithfully demonstrate unique ILC features and can serve as invaluable pre-clinical translational platforms for validating candidate ILC genetic drivers and testing novel therapeutics.